Both the two cells are TNBC cell lines? What's the differrences between them? Especially, the differences of the sensitivity to photodynamic therapy. It is appretiated if references will be attached.
hi
Check these papers
Article Triple Negative Breast Cancer Cell Lines: One Tool in the Se...
Article Holliday, D. L. & Speirs, V. Choosing the right cell line fo...
Article Synergistic Effect of Photodynamic Treatment and Doxorubicin...
https://www.nature.com/articles/s41598-020-78241-1
MDA-MB-468 is a basal BC cell line while MDA-MB-231 is a claudin-low cell line - a point Hamed Helal made above, to his credit - with claudin-3, claudinin-4 and claudinin-7 low, and typically with low Ki67 and E-cadherin, in contrast to MDA-MB-468 absent these and itself with high Ki-67 and as I noted, MDA-MB-231 shows enrichment for markers associated with EMT and the expression of features associated with mammary cancer stem cells (CSCs), such as the CD44+CD24-/low phenotype, features NOT shared with MDA-MB-468, so they can be different in molecular and phenotypic behavior. Many studies on potentially active agents for triple negative breast cancer disease have been conducted using, indifferently, MDA-MB-231 or MD-MD-468 (there are dozens of examples, many right here in ResearchGate), but MDA-MB-468 most closely maps basal tumors (EGFR-positivity and cytokeratins 5/6) while MDA-MB-231 closely maps not basality, but rather the new claudin-low (E-cadherin, claudin-3, claudinin-4 and claudinin-7 low) molecular subtype, and clearly these are vastly different in molecular and phenotypic behavior, with MDA-MB-468 being highly proliferative and prognostically highly compromised relative to MDA-MB-231 (which is NOT highly proliferative), so it matters vastly which cancer cell line is chosen, and of course it will also matter vastly as to outcome obtained from any given preclinical study trying to determine the efficacy and responsivity of a particular therapeutic agent against one versus the other cell line, yet basic scientists often slur these together as "triple-negative" cell lines. So MDA-MB-231 is characterized more critically by claudin-3 and claudinin-4 downregulation, low expression of the Ki-67 proliferation marker, enrichment for markers associated with EMT (the epithelial-mesenchymal transition), and, importantly, the expression of features associated with mammary cancer stem cells (CSCs), such as the CD44+CD24-/low phenotype, features NOT shared with MDA-MB-468.
Hello Lan Mei
Please refer to the research articles below for the said cell lines and their sensitivity to photodynamic therapy.
Article Drug-loaded Photosensitizer-Chitosan Nanoparticles for Combi...
https://doi.org/10.3390/molecules25225317
Hope this helps.
Best.
- Badges
- Science topic
- Similar topics
- Biological Science
- Molecular Cell Biology
- Culture Cells
- Cell Line